cvs caremark glp-1 coverage Expands Formulary CVS Is Dropping Zepbound. Here

Hot topics from randomized controlled trials

Jura, N., Archer, H

Common problems include: Incomplete paperwork: missing fields, unsigned forms, or omitted chart attachments Weak evidence of medical necessity: the diagnosis is present, but the supporting history is thin Missing comorbidity documentation: the condition may be in the patients history but not clearly included in the submission No proof of prior lifestyle effort: many plans want evidence, not just a statement Step therapy gaps: if the plan requires trying another option first, that requirement has to be addressed directly Some patients also run into a coverage issue that has nothing to do with their health

During the appeal, options include paying cash with a plan for retroactive reimbursement if the appeal succeeds, using the manufacturer savings programs, or starting a personalized treatment plan with a compounded GLP-1 through a telehealth provider while the review is pending

First, because of the small number of studies meeting the inclusion criteria, only 5 reports were extracted and merged, which increased the uncertainty of the results